Skip to main content

Table 4 Antimicrobial resistance of Acinetobacter baumannii and Pseudomonas aeruginosa isolates to the tested antibiotics

From: Shifting trends in bacteriology and antimicrobial resistance among gastrointestinal fistula patients in China: an eight-year review in a tertiary-care hospital

Resistance rate (%)
Isolate/Antibiotics 2008–2011 2012–2015 Total P for Trend Test
Acinetobacter baumannii
 AMP 96.43 100.00 98.55 0.223
 SAM 90.48 100.00 96.77 0.045
 TZP 96.30 95.00 95.52 0.801
 SXT 95.24 73.17 80.65 0.037
 CRO 94.44 100.00 98.31 0.128
 CTX 100.00 100.00 100.00
 CAZ 88.89 100.00 95.59 0.029
 FEP 96.30 100.00 98.53 0.214
 IPM 96.30 95.12 95.59 0.818
 LVX 66.67 56.10 60.29 0.383
 CIP 95.24 97.56 96.77 0.624
Pseudomonas aeruginosa
 AMK 31.82 22.22 25.86 0.418
 SAM 100.00 100.00 100.00
 TZP 60.87 33.33 44.07 0.038
 ATM 58.82 75.00 61.90 0.549
 SXT 100.00 97.22 98.11 0.488
 CRO 100.00 100.00 100.00
 CTX 100.00 100.00 100.00
 CAZ 69.57 61.11 64.41 0.508
 FEP 65.22 50.00 55.93 0.251
 IPM 73.91 58.33 64.41 0.223
 LVX 34.78 44.44 40.68 0.461
 CIP 38.89 41.18 40.38 0.873
Not all tested antibiotics are listed
  1. AMK Amikacin, SAM Ampicillin/Sulbactam, TZP piperacillin-tazobactam, ATM Aztreonam, SXT Trimethoprim/Sulfamethoxazole, CRO Ceftriaxone, CTX cefotaxime, CAZ ceftazidime, FEP cefepime, IPM imipenem, LVX levofloxacin, CIP ciprofloxacin
  2. Data in boldface reflected p values < 0.05